Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MGRX vs CISS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CISS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

CISS Overall Winner 6-Pillar Tally: MGRX 2 – 4 CISS Matrix Metrics: MGRX 2 – 5 CISS

As of Nov 20, 2026, C3is Inc. (CISS) is the stronger overall head-to-head candidate over Mangoceuticals, Inc. (MGRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGRX carries a Unified Composite Score of 40.5/100 (SELL) at $0.12 (N/M Forward P/E, -4173.6% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin).

  • Composite vs. Pillar Nuance: While MGRX currently prints a higher short-term Unified Composite Score (40.5/100 SELL vs. CISS 33.6/100 SELL), CISS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.6% vs. -4173.6% operating margin) and revenue trajectory (+249.0% vs. -59.1% YoY).
  • Defensive Composite Rating Caution: Although CISS compares more favorably head-to-head, both MGRX (40.5/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MGRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MGRX vs CISS
MGRX NASDAQ
Mangoceuticals, Inc. Common Stock
Services-Misc Health & Allied Services, Nec
$0.12
-7.55% 1D
Market Cap $3.0M
TTM Revenue $315,227
Forward P/E N/M
Beta / 30D Vol 1.53β · 87% Vol
Unified Composite Score
40.5 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.6%), weak momentum, RSI 21
RSI-14: 21.2 · SMA20: $0.20 · SMA50: $0.32
CISS NASDAQ Head-to-Head Winner
C3is Inc. Common Stock
Deep Sea Foreign Transportation Of Freight
$1.23
+4.24% 1D
Market Cap $991,199
TTM Revenue $36.2B
Forward P/E N/M
Beta / 30D Vol 11.91β · 1054% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 5.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $1.05 · SMA50: $0.95

6-Pillar Scorecard Institutional Category Breakdown (MGRX 2 – 4 CISS)

Columns: Metric · MGRX · CISS
1. Valuation Multiples MGRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.8x N/M
2. Growth & Scale CISS
Revenue Growth (YoY) -59.1% +249.0%
Earnings Growth (YoY) +0.0% +193.3%
TTM Revenue (USD) $315,227 $36.2B
Market Cap $3.0M $991,199
3. Profitability & Quality CISS
Gross Margin 54.4% 68.1%
Operating Margin -4173.6% 24.6%
Net Profit Margin 0.0% 27.4%
Return on Equity (ROE) -95.1% 17.1%
4. Balance Sheet & Cash Flow CISS
Cash Generation (TTM) -$4.9M $13.4B EBITDA
Cash Flow Margin N/A 36.9% EBITDA Mgn
Net Cash / Leverage $119,461 Net Debt (0.02x D/E) $384.31 Book/Sh · 17.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGRX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CISS
OpEx & R&D Intensity N/A 43.5% of Rev ($15.8B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Health Information Services Operator Marine Shipping Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MGRX (2) vs CISS (5)
Institutional Metric MGRX CISS Criterion Row Edge
Market Capitalization
Scale
$3.0M $991,199 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-59.1% +249.0% Higher Growth CISS
Operating Margin (TTM)
Profitability
-4173.6% 24.6% Higher Margin CISS
Net Profit Margin
Profitability
0.0% 27.4% Higher Margin CISS
Return on Equity (ROE)
Capital Efficiency
-95.1% 17.1% Higher ROE CISS
52-Week Range Position
Momentum
0% ($0–$1) 20% ($0–$6) Stronger Trend CISS
Beta / 30D Volatility
Risk Regime
1.53β · 87% Vol 11.91β · 1054% Vol Lower Realized Risk MGRX
Unified Institutional Score
Composite Signal
40.5 / 100 (SELL) 33.6 / 100 (SELL) Higher Composite MGRX
Trailing 12M Revenue (USD)
Operating Scale
$315,227 $36.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.4% 68.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.9M ($119,461 Net Debt (0.02x D/E)) $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CISS +184.64 pp
MGRX: -49.41% · CISS: +135.23%
3M Horizon CISS +14.87 pp
MGRX: -67.74% · CISS: -52.87%
6M Horizon CISS +24.71 pp
MGRX: -72.59% · CISS: -47.88%
1Y Horizon CISS +64.58 pp
MGRX: -90.03% · CISS: -25.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MGRX Revenue CISS Revenue MGRX Op. Margin CISS Op. Margin Margin Leader
FY2022 $0M N/A -22279.7% N/A MGRX
FY2023 $0M $30M -1260.3% 36.3% CISS
FY2024 $0M $40M -1294.4% 23.8% CISS
FY2025 $0M $30M -3954.3% 3.9% CISS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MGRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MGRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CISS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MGRX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $3.0M market capitalization and -4173.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CISS Moat Profile Scale & Operating Efficiency Moat
Marine Shipping Operator
Competes within the Marine Shipping value chain with $991,199 market capitalization and 24.6% operating margin.
OpEx & R&D Reinvestment 43.5% of Rev ($15.8B)
90D Engineering Disclosures 0 Published

Investor FAQ MGRX vs CISS Key Questions & Quantitative Answers

As of Nov 20, 2026, C3is Inc. (CISS) is the stronger overall head-to-head candidate over Mangoceuticals, Inc. (MGRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGRX carries a Unified Composite Score of 40.5/100 (SELL) at $0.12 (N/M Forward P/E, -4173.6% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin). Composite vs. Pillar Nuance: While MGRX currently prints a higher short-term Unified Composite Score (40.5/100 SELL vs. CISS 33.6/100 SELL), CISS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.6% vs. -4173.6% operating margin) and revenue trajectory (+249.0% vs. -59.1% YoY). Defensive Composite Rating Caution: Although CISS compares more favorably head-to-head, both MGRX (40.5/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MGRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CISS leads the Growth & Scale pillar: MGRX posts -59.1% YoY revenue growth and +0.0% YoY earnings growth on $315,227 TTM revenue (54.4% gross margin, -4173.6% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), MGRX cumulative revenue shifted N/A while CISS shifted +0.0%. In operating R&D and SG&A reinvestment, MGRX deploys N/A (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.

MGRX screens cheaper on headline valuation multiples. MGRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (unreported FCF margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGRX (-95.1% ROE) versus CISS (17.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MGRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 87% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.